Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.
Shandong Xinhua Pharmaceutical Company Limited announced that it has received the Drug Registration Certificate for Isavuconazonium Sulfate for Injection from the National Medical Products Administration. This approval marks a significant milestone for the company, allowing it to produce and market this prescription drug, potentially enhancing its market position and offering new opportunities for growth within the pharmaceutical sector.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, primarily engaged in the production and sale of prescription drugs. The company focuses on developing chemical drugs and has a market presence in the pharmaceutical industry.
Average Trading Volume: 4,260,784
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.58B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.